Geoff Green

CEO
Longeveron
(NASDAQ: LGVN)

Geoff Green, CEO Geoff Green has been with Longeveron since 2016, and is a veteran of the life sciences and drug development industry. A versatile executive with a career spanning 25 years in both public and private companies, Mr. Green has held a variety of leadership roles throughout his time in the industry. Prior to joining Longeveron, he was VP of Operations at Partikula, VP, Business Development & Clinical Affairs at Accu-Break Pharmaceuticals, President and Acting CEO of DOR BioPharma (now Soligenix (NAS: SNGX)), VP of Business Development & Operations at Heart Genomics, and Director of Clinical Affairs at Innovative Drug Delivery Systems.

Early in his career he spent several years managing oncology clinical trials at Memorial Sloan-Kettering Cancer Center, and as a research associate at Paramount Capital, where he managed clinical trials for several portfolio companies. Mr. Green received a B.A. in biology from Kenyon College, and an M.B.A. from Barry University’s Andreas School of Business.